Works matching IS 21534888 AND DT 2022 AND VI 13 AND IP 5
Results: 21
Nubeqa Now Approved for Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 15
- Publication type:
- Article
FDA Accelerates the Approval of Enhertu for the Treatment of HER2-Low Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 15
- Publication type:
- Article
Enhertu First Drug Approved for HER2-Positive Non–Small- Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 15
- Publication type:
- Article
Imbruvica Now Approved for Treatment of Pediatric Patients with Chronic GVHD, Including New Oral Suspension Formulation.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 13
- Publication type:
- Article
COVID-19’s Impact on Radiation Oncology and Healthcare.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 13
- By:
- Publication type:
- Article
Biden’s Cancer ‘Moonshot’ Contradiction.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 12
- Publication type:
- Article
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 12
- Publication type:
- Article
The Drug Pricing ‘Slippery Slope’.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 11
- Publication type:
- Article
CAR T-Cell Effective as Second-Line Treatment in Transplant-Ineligible Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 11
- By:
- Publication type:
- Article
Pemazyre Now Approved for Relapsed or Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 10
- Publication type:
- Article
Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 9
- By:
- Publication type:
- Article
Imfinzi Receives New Indication for Locally Advanced or Metastatic Biliary Tract Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 8
- Publication type:
- Article
Novel Approach to the Treatment of Desmoid Tumors Shows Great Promise.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 7
- By:
- Publication type:
- Article
NEW INDICATIONS Retevmo Approved for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors and Locally Advanced or Metastatic RET Fusion– Positive NSCLC.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 6
- Publication type:
- Article
Integrating Digital Health Technology into Cancer Care.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 6
- By:
- Publication type:
- Article
Tabrecta Receives Regular FDA Approval for Treatment of Metastatic NSCLC.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 5
- Publication type:
- Article
Lytgobi Receives Accelerated Approval for Cholangiocarcinoma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 5
- Publication type:
- Article
Increased Biosimilar Use Translates to Substantial Savings for Oncology Practices.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 1
- By:
- Publication type:
- Article
DETERMINATION Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 1
- By:
- Publication type:
- Article
A Path Toward Clinical Trial Diversity.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 1
- By:
- Publication type:
- Article
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 5, p. 1
- By:
- Publication type:
- Article